Bank of Montreal
NBIX icon

Bank of Montreal’s Neurocrine Biosciences NBIX Stock Holding History

Bank of Montreal’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-28,800
Closed -$3.28M – 4202
2023
Q3 		$3.28M Buy
+28,800
New +$3.03M ﹤0.01% 1468

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of Montreal's NBIX Position: Q1 2026 in Review

Bank of Montreal increased its Neurocrine Biosciences (NBIX) stake by 31% in Q1 2026, buying an estimated $978K and bringing the position to 31,003 shares worth $4.08M. The position accounts for ﹤0.01% of the portfolio, ranked #1386.

Bank of Montreal first reported a position in NBIX in Q2 2014 and has held it in 45 quarters since. The position peaked at $71.1M in Q3 2021. 696 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Bank of Montreal held 31,003 shares of Neurocrine Biosciences worth $4.08M as of Q1 2026.
  • Bank of Montreal bought 7,368 Neurocrine Biosciences shares in Q1 2026, an estimated $978K.
  • Neurocrine Biosciences made up ﹤0.01% of Bank of Montreal's portfolio in Q1 2026, its #1386 holding.
  • Bank of Montreal first reported a position in Neurocrine Biosciences in Q2 2014 and has held it in 45 quarters since.
  • Bank of Montreal's Neurocrine Biosciences position peaked at $71.1M in Q3 2021.
  • 696 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Bank of Montreal's 13F filing for Q1 2026, filed 13 May 2026.